Latest Safety News

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.

Altech Batteries, in partnership with AMPower, has launched a next-generation 384 V / 15 kWh sodium nickel chloride UPS battery designed specifically for Europe's pipeline infrastructure, promising enhanced safety and reliability in explosive environments.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.

Acusensus Limited has landed its first major automated enforcement contract in the US with Connecticut, marking a significant milestone in its American growth strategy. The five-year deal, valued at US$22.6 million, will see the deployment of AI-enabled speed enforcement technology across work zones.

The U.S. FDA has lifted the clinical hold on Neurizon Therapeutics’ lead drug candidate NUZ-001, enabling its entry into a major ALS platform trial set for Q4 2025. This regulatory milestone accelerates the company’s clinical development and opens doors for broader neurodegenerative applications.

Electro Optic Systems has landed a significant A$108 million contract to supply remote weapon systems for the Australian Defence Force’s LAND 400-3 project, integrating its technology with Hanwha’s Redback Infantry Fighting Vehicles.

Locksley Resources has gained critical regulatory approval and secured contractors to advance its Mojave Project, accelerating exploration of antimony and rare earth elements in California.

Kelsian Group has postponed the start of its new Kangaroo Island ferry service to June 2026, citing vessel delivery delays and aiming to avoid peak season disruptions. The new ferries will significantly increase capacity and offer fare discounts to residents during the transition.

Altech has detailed its Sodium Nickel Chloride (SNC) battery technology designed specifically for hazardous explosive environments, highlighting superior safety, longevity, and minimal maintenance compared to traditional battery chemistries.

Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.

QMines Limited has announced a fully underwritten $1.5 million Share Purchase Plan for existing shareholders, complementing a recent $7.5 million placement to fund exploration at its Mt Mackenzie gold and silver project.